Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.

Selecta and Sobi posted positive topline results from their Phase III trials of SEL-212 in chronic refractory gout • Source: Shutterstock

Selecta Biosciences, Inc.’s and Swedish Orphan Biovitrum AB’s (Sobi’s) Phase III results for SEL-212 in gout will likely be sufficient for the drug’s US Food and Drug Administration approval, but they also point to potential commercial advantages over Horizon Therapeutics plc’s Krystexxa (pegloticase) in terms of adverse events, convenience and issues that affect adherence.

Selecta and Sobi announced 21 March positive topline results from the DISSOLVE I and DISSOLVE II trials, which were placebo-controlled...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D